Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.
Psychopharmacology February 1, 2018 John Hartberg, Simone Garrett-Walcott, Angelo De Gioannis 66 citations
In a review of 37 outpatients receiving long-term oral ketamine for treatment-resistant depression and PTSD, inpatient psychiatric hospital days dropped by 70% and admissions by 65% after treatment began. The required ketamine dose remained stable over time with no signs of tolerance, and no serious adverse events or long-term negative effects were reported. Oral ketamine may offer a more accessible alternative to intravenous or intramuscular ketamine, though further research into its safety and efficacy is warranted.